羟基脲用于尼日利亚镰状细胞贫血儿童卒中一级预防(SPRING):双盲、多中心、随机、3期试验
SPRING为双盲、平行组、随机对照3期试验,在尼日利亚三所教学医院纳入220例5-12岁镰状细胞贫血且经颅多普勒流速异常的儿童,1:1随机接受低剂量(10 mg/kg/日)或中等剂量(20 mg/kg/日)口服羟基脲。中位随访2.4年后,低剂量组109例中3例(3%)发生卒中,中等剂量组111例中5例(5%)发生卒中,卒中发生率比为0.62(95%CI 0.10-3.20,p=0.77)。
要点
- 低剂量组卒中发生率1.19/100人年,中等剂量组1.92/100人年,发生率比0.62(95%CI 0.10-3.20,p=0.77)。
- 全因住院发生率比1.71(95%CI 1.15-2.57,p=0.0071),低剂量组27.43/100人年 vs 中等剂量组16.08/100人年。
- 无 participant 因骨髓抑制停用羟基脲。
核心结论
- 与低剂量羟基脲相比,中等剂量羟基脲组卒中发生率无差异。
- 次要分析提示中等剂量组可能降低全因住院发生率。
- 这些发现为低剂量羟基脲用于有卒中风险的镰状细胞贫血儿童提供了循证指南。
研究设计与样本
- SPRING为双盲、平行组、随机对照3期试验,在尼日利亚三所教学医院开展。
- 纳入5-12岁镰状细胞贫血且经颅多普勒流速异常的儿童,1:1随机分配至低剂量(10 mg/kg/日)或中等剂量(20 mg/kg/日)口服羟基脲,每日一次。
- 采用排列区组分配方案(区组大小4),按性别和中心分层,除药师和统计师外分配隐藏。
- 主要结局为经中心裁定的初始卒中或短暂性脑缺血发作;次要结局为全因住院。
- 计划最低随访3.0年后因无效提前终止;共220例参与者随机分配,中位年龄7.2岁(IQR 5.5-8.9),女性114例(52%),中位随访2.4年(IQR 2.0-2.8)。
主要发现
- 低剂量组109例中3例(3%)发生卒中,发生率1.19/100人年;中等剂量组111例中5例(5%)发生卒中,发生率1.92/100人年;发生率比0.62(95%CI 0.10-3.20,p=0.77)。
- 全因住院发生率比为1.71(95%CI 1.15-2.57,p=0.0071),低剂量组27.43/100人年 vs 中等剂量组16.08/100人年。
- 无参与者因骨髓抑制停用羟基脲。
- 所有参与者均为尼日利亚人,族裔分布:豪萨族179例(82%)、富拉尼族25例(11%)、其他族裔16例(7%)。
关键数值与推荐
- 低剂量羟基脲为10 mg/kg/日口服,每日一次。
- 中等剂量羟基脲为20 mg/kg/日口服,每日一次。
- 主要结局为初始卒中或短暂性脑缺血发作,经中心裁定。
临床怎么用
- 作者认为这些发现为低剂量羟基脲用于有卒中风险的镰状细胞贫血儿童提供了循证指南。
局限性
- 试验因无效提前终止。
- 次要分析提示中等剂量组可能降低全因住院发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In high-income countries, standard care for primary stroke prevention in children with sickle cell anaemia and abnormal transcranial Doppler velocities results in a 92% relative risk reduction of strokes but mandates initial monthly blood transfusion. In Africa, where regular blood transfusion is not feasible for most children, we tested the hypothesis that initial moderate-dose compared with low-dose hydroxyurea decreases the incidence of strokes for children with abnormal transcranial Doppler velocities. METHODS: SPRING is a double-blind, parallel-group, randomised, controlled, phase 3 trial of children aged 5-12 years with sickle cell anaemia with abnormal transcranial Doppler velocities conducted at three teaching hospitals in Nigeria. For randomisation, we used a permuted block allocation scheme with block sizes of four, stratified by sex and site. Allocation was concealed from all but the pharmacists and statisticians. Participants were assigned in a 1:1 ratio to low-dose (10 mg/kg per day) or moderate-dose (20 mg/kg per day) oral hydroxyurea taken once daily with monthly clinical evaluation and laboratory monitoring. The primary outcome was initial stroke or transient ischaemic attack, centrally adjudicated. The secondary outcome was all-cause hospitalisation. We used the intention-to-treat population for data analysis. The trial was stopped early for futility after a planned minimum follow-up of 3·0 years to follow-up for participants. This trial was registered with ClinicalTrials.gov, number NCT02560935. FINDINGS: Between Aug 2, 2016, and June 14, 2018, 220 participants (median age 7·2 years [IQR 5·5-8·9]; 114 [52%] female) were randomly allocated and followed for a median of 2·4 years (IQR 2·0-2·8). All participants were Nigerian and were from the following ethnic groups: 179 (82%) people were Hausa, 25 (11%) were Fulani, and 16 (7%) identified as another ethnicity. In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77). The incidence rate ratio of hospitalisation for any reason was 1·71 (95% CI 1·15-2·57, p=0·0071), with higher incidence rates per 100 person-years in the low-dose group versus the moderate-dose group (27·43 vs 16·08). No participant had hydroxyurea treatment stopped for myelosuppression. INTERPRETATION: Compared with low-dose hydroxyurea therapy, participants treated with moderate-dose hydroxyurea had no difference in the stroke incidence rate. However, secondary analyses suggest that the moderate-dose group could lower incidence rates for all-cause hospitalisations. These findings provide an evidence-based guideline for the use of low-dose hydroxyurea therapy for children with sickle cell anaemia at risk of stroke. FUNDING: National Institute of Neurological Disorders and Stroke.
引用
- Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022. PMID: 34971579. doi:10.1016/S2352-3026(21)00368-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。